Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gh Research Plc
(NQ:
GHRS
)
11.80
+0.17 (+1.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
89,861
Open
11.72
Bid (Size)
11.00 (1)
Ask (Size)
11.64 (1)
Prev. Close
11.63
Today's Range
11.41 - 12.22
52wk Range
5.050 - 14.99
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
June 09, 2024
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 05, 2024
Via
Benzinga
Performance
YTD
+120.56%
+120.56%
1 Month
-4.53%
-4.53%
3 Month
+11.43%
+11.43%
6 Month
+123.48%
+123.48%
1 Year
-4.99%
-4.99%
More News
Read More
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
Via
Talk Markets
GH Research: Q4 Earnings Insights
February 29, 2024
Via
Benzinga
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
May 03, 2024
Via
InvestorPlace
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024
From
GH Research PLC
Via
GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
Via
Talk Markets
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
April 12, 2024
Via
Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
March 30, 2024
Via
Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
March 11, 2024
Via
Talk Markets
Exposures
Product Safety
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
Via
Talk Markets
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
February 29, 2024
Via
Benzinga
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024
From
GH Research PLC
Via
GlobeNewswire
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
February 18, 2024
Via
Talk Markets
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
Via
Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Via
Benzinga
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
January 18, 2024
From
GH Research PLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.